Close
Close

Post-Translational Modification (PTM) Specific Antibody Discovery Service by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

Identify antibodies that bind modified states of proteins with high affinity and exquisite specificity between modified and unmodified forms to power next-gen therapeutics and diagnostics.

PTM-Specific
Rarely found binders that recognize specific post-translational modifications (PTMs) with high precision (phosphorylation, acetylation, methylation etc.) 		No Backbone Cross-Reactivity
Our stringent counter-selection strategies remove unmodified protein binders in order to guarantee ultimate specificity.
Developability by Design
We prioritize candidates with favorable biophysical properties, reducing downstream development risks and timelines. 		Weeks to High-Affinity Leads
Go from target to a panel of validated, PTM-specific antibody candidates in as little as 10-14 weeks.

Anti-PTM Antibody Discovery

Antibody discovery against post-translational modifications (PTMs) of proteins can be challenging. Targets with inherently low immunogenicity and high homology to the unmodified protein backbone are plagued by high rates of project failure and unmet timelines. Creative Biolabs overcomes these hurdles by integrating our vast, high-diversity premade antibody libraries with expert, PTM-focused screening strategies. The result is a faster path to high-specificity, high-affinity, and downstream-ready candidates engineered for success.

Screening Platform: Precision, Speed, and Strategy

At Creative Biolabs, our phage and yeast display platforms are finely tuned to navigate the immense diversity of our libraries, deploying stringent counter-selection protocols that systematically eliminate binders to the unmodified backbone. We directly address the core challenges of PTM antibody discovery which is high background, low affinity, and poor discrimination. We deliver reliable reagents that fuel discovery, diagnostic, and therapeutic programs with minimized off-target effects and maximum biological relevance.

Get Started - Request Your Quote Today

Specialized Related Services

Our platform's power lies in its ability to dissect complex epitopes. Anti-Epitope Antibody Discovery is a broad category of services we offer for the most challenging targets:

Fig.1 Premade Antibody Library based TCR-Like Antibody Discovery Service. (Creative Biolabs Authorized)

Premade Antibody Library based TCR-Like Antibody Discovery Service
Generating antibodies against transient peptide-MHC complexes recognized by T-cells

Fig.2 Premade Antibody Library based Anti-PTM Antibody Discovery Service. (Creative Biolabs Authorized)

Premade Antibody Library based Anti-Idiotype Antibody Discovery Service
Targeting the unique variable regions of other antibodies

Ask About Turnaround & Pricing

Screening Workflow: A Strategy-First Approach

Our end-to-end workflow is designed to de-risk PTM antibody discovery at every stage, moving rapidly from vast library diversity to a panel of validated, specific, and developable leads.

  • Fig.3 Discovery Design & PTM Antigen Strategy. (Creative Biolabs AI)
    Discovery Design & PTM Antigen Strategy

    Collaborative strategy development

    Optimized PTM antigen & counter-selection reagent design

    Engineered for maximum specificity from day one

    Upfront mitigation of common failure points

  • Fig.4 Biopanning & Counter-Selection. (Creative Biolabs AI)
    Biopanning & Counter-Selection

    Multi-round, high-stringency panning protocols

    Aggressive depletion of unmodified backbone binders

    Forced enrichment of rare, PTM-specific clones

  • Fig.5 Single-Clone Specificity Screening. (Creative Biolabs AI)
    Single-Clone Specificity Screening

    High-throughput ELISA/BLI screening

    Direct comparison: PTM vs. non-PTM target binding

    Data-driven ranking by specificity ratio

  • Fig.6 Functional Confirmation & Epitope Strategy. (Creative Biolabs AI)
    Functional Confirmation & Epitope Strategy

    Cell-based assays to validate biological relevance

    Epitope binning to ensure a diverse lead panel

    Prioritization of functionally active candidates

  • Fig.7 Sequence Analytics & Liability Filtering. (Creative Biolabs AI)
    Sequence Analytics & Liability Filtering

    NGS-driven analysis of sequence diversity

    In silico screening for developability liabilities (e.g., aggregation, isomerization)

    Early de-risking before investment in IgG format

  • Fig.8 IgG Conversion & Developability Panel. (Creative Biolabs AI)
    IgG Conversion & Developability Panel

    Top candidates reformatted to full IgG

    Rigorous biophysical assessment: solubility, thermal stability, aggregation

    Confirmation of specificity and affinity in final format

  • Fig.9 Reporting & Tech Transfer. (Creative Biolabs AI)
    Reporting & Tech Transfer

    Comprehensive data package delivery

    Full access to all sequences and raw data

    Seamless handoff to accelerate your internal program

Discuss Your Screening Strategy with an Expert

Premade Antibody Libraries: Engineered for Success

Our libraries are the foundation of our discovery engine, designed for broad epitope coverage and superior developability.

Human Camel Llama Alpaca Humanized VHH
Antibody Library ID Display Technology Library Format Library Size
HuScL-6
☆Highly Recommended 		pIII-fusion, Phagemid Phage Display Naïve scFv 2.1×1011
HuScL-3S pIII-fusion, Phagemid Phage Display Semi-synthetic scFv >1.0×1011
HuFabL-4 pIII-fusion, Phagemid Phage Display Naïve Fab 1.9×1010
HuFabssL-1 pIII-fusion, Phagemid Phage Display Naïve & synthetic Fab 1.8×1010

Not sure which library fits? Request a Quote

Case Study: Discovery of PTM-Specific Antibodies

Phospho-Specific Lead for a Kinase Pathway Target
Project Goal Develop a high-affinity human monoclonal antibody targeting a specific phosphorylated residue on a Protein Kinase to enable targeted signaling research.
The Challenge Phospho-State Discrimination: The antibody must distinguish between the phosphorylated and non-phosphorylated versions of the same peptide sequence.
Our Solution: Strategic Synthetic Screening We leveraged our Synthetic Human scFv Library to isolate rare, high-specificity clones through a multi-stage biopanning strategy:
Positive Selection: Utilizing conjugated phospho-peptides to capture potential binders.
In-Solution Depletion: Introducing high concentrations of free non-phospho-peptides during the binding phase. This "competitive decoy" strategy effectively eliminated clones binding to the common backbone.
Stringent Washing: Applying high-stringency buffers to ensure only high-affinity phospho-specific binders remained.
Key Outcomes & Data Validation
Fig.10 Graph illustrating the library screening outcomes. (Creative Biolabs Original) Fig.11 Graph displaying the specificity validation results. (Creative Biolabs Original)
Exceptional Enrichment
Analysis of the panning output showed a enrichment trend, indicating the successful isolation of target-specific populations. 		Elite Specificity
Validation of the top positive clones demonstrated the signal-to-background ratio when comparing binding signals on phospho-peptide vs. non-phospho-peptide.

Ready to Build Your Success Story? Contact Us

Related Services

Find additional antibody discovery services tailored to your specific needs.

Fig.12 Functional human antibody discovery. (Creative Biolabs AI)

Functional Human Antibody Discovery

Fig.13 Anti-peptide/protein antibody discovery. (Creative Biolabs AI)

Anti-Peptide/Protein Antibody Discovery

Fig.14 Anti-Cell-based target antibody discovery. (Creative Biolabs AI)

Anti-Cell-based Target Antibody Discovery

Fig.15 Bi-functional antibody discovery. (Creative Biolabs AI)

Bi-functional Antibody Discovery

Fig.16 Cell-internalizing antibody discovery. (Creative Biolabs AI)

Cell-Internalizing Antibody Discovery

Fig.17 Anti-epitope antibody discovery. (Creative Biolabs AI)

Anti-Epitope Antibody Discovery

Fig.18 Antibody discovery for immunotherapy. (Creative Biolabs AI)

Antibody Discovery for Immunotherapy

Fig.19 Anti-disease-specific target antibody discovery. (Creative Biolabs AI)

Anti-Disease-Specific Target Antibody Discovery

Why Choose Us?

Synergy for PTM Targets

Our massive 1011 diversity libraries combined with stringent counter-selection protocols are engineered to isolate rare PTM-specific binders that other methods miss.

Specificity by Design

We build your project around a robust negative selection strategy from day one, ensuring candidates demonstrate clean discrimination between modified and unmodified forms early.

Accelerated PTM Timelines

Our streamlined, end-to-end platform compresses the complex hit-to-lead process for PTM targets into a matter of weeks, not months.

Radical Transparency

You get end-to-end data access, including NGS clonotype analysis, enrichment curves, and ranked specificity data, empowering confident, audit-ready decisions.

QA-Backed Rigor for Downstream Success

Reproducible biophysical panels and validated human frameworks ensure the antibodies we deliver are stable, manufacturable, and ready for the next stage.

Inquiry & Project Initiation

Ready to discover the PTM-specific antibodies that will drive your next breakthrough? Contact Us for more information. Our team of experts is ready to design a discovery campaign tailored to your exact scientific goals.

To help us provide the most accurate proposal, please include the following in your inquiry:

FAQ

  1. What is the typical timeline for an anti-PTM screening project?

    A standard project runs 10-16 weeks from strategy design to the delivery of a validated IgG mini-panel, though this can vary based on antigen complexity and assay requirements.

  2. How do you guarantee specificity against the unmodified protein?

    Our workflow is built on stringent counter-selection, where we actively deplete binders to the unmodified protein/peptide during the panning process. This is followed by high-throughput screening that directly compares binding to the PTM target versus the unmodified backbone, ensuring we only advance clones with high specificity ratios.

  3. What starting materials do I need to provide?

    Ideally, you would provide the target protein sequence, the specific PTM of interest, and its location. We can assist with the synthesis of the modified antigen and the unmodified counter-selection material as part of the project scope.

  4. Who owns the intellectual property (IP) for the discovered antibodies?

    Our standard engagement models ensure that you retain full IP ownership of the final antibody sequences delivered for your target.


All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Related Sections
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2026 Creative Biolabs. | Contact Us